Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
uPAR-PET/MRI in Glioblastoma Multiforme
NCT02945826Phase 2Unknown
- Sponsor
- Rigshospitalet
- Start
- Jan 2017
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-NOTA-AE105 in glioblastoma multiforme (GBM), sponsored by Rigshospitalet. Primary endpoints: uPAR PET/MRI imaging of uPAR expression at 1 hour and Overall Survival at 36 months. Status: unknown.
02
Drugs
68Ga-NOTA-AE105
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02945826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02945826.